Recurrent Head and Neck Squamous Cell Carcinoma Active Not Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0057896 (Recurrent Head and Neck Squamous Cell Carcinoma)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03823131Tavo With Electroporation, Pembrolizumab, and Epacadostat in Patients With Unresectable Head and Neck CancerTreatment